Omontys Lawsuit

In February 2013, an Omontys recall was issued following reports of severe and sometimes fatal reactions caused by side effects of the anemia drug given to patients following dialysis treatment.

STATUS OF OMONTYS LAWSUITS: Following the decision to remove the medication from the market, lawyers are evaluating the potential for Omontys recall lawsuits as a result of the drug makers failure to adequately warn about the risk of anaphylaxis reactions and other problems from Omontys.

>>SUBMIT INFO FOR REVIEW BY AN OMONTYS LAWYER<<

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

MANUFACTURER: Affymax and Takeda Pharmaceuticals

OVERVIEW: Omontys (peginesatide) was approved in 2012 for treatment of anemia in dialysis patients. It is designed to be injected once per month, but it was not indicated or recommended for individuals with chronic kidney disease who were not on dialysis, or as a general treatment for anemia. It was also never shown to improve symptoms, physical functioning or health-related qualify of life.

An estimated 25,000 patients were treated with the medication, most of which came through a pilot program at a number of Fresenius dialysis centers.

OMONTYS RECALL In February 2013, the manufacturers recalled Omontys following reports of serious hypersensitivity reactions, including several severe and even fatal events.

At least 19 patients who received the drug through the pilot program suffered severe reactions to Omontys, resulting in the need for immediate medical treatment and often hospitalization. In at least three of those cases, patients died following Omontys use.

According to information released by the manufacturer, the Omontys allergic reactions appear to occur within 30 minutes of the first injection in about 0.2% of cases, with about a third of those being serious and sometimes including anaphylaxis. Fatal reactions may occur in about 0.02% of all cases, according to the manufacturers.

It is unclear how many of the actual Omontys problems were properly reported and documented, as side effects and adverse events caused by prescription medications are typically only reported in about 1% to 10% of all cases.

Tags:
Image Credit: |

0 Comments

Share Your Story With Our Community

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Management of Ozempic Lawsuit Pretrial Proceedings To Be Reassigned Following Death of MDL Judge
Management of Ozempic Lawsuit Pretrial Proceedings To Be Reassigned Following Death of MDL Judge (Posted today)

The judge overseeing Ozempic lawsuits consolidated in federal court has died, requiring a new judge to be assigned to oversee coordinated pretrial proceedings over claims the diabetes drug and similar medications caused stomach paralysis and other intestinal complications.

Baby Food Injury Lawyers Appointed To Leadership Roles in Autism, ADHD Lawsuits Over Heavy Metal Contamination
Baby Food Injury Lawyers Appointed To Leadership Roles in Autism, ADHD Lawsuits Over Heavy Metal Contamination (Posted 2 days ago)

A group of 19 plaintiffs' lawyers have been appointed to serve in various leadership position during the consolidated pretrial proceedings for all baby food injury lawsuits, taking actions that benefit all families pursuing claims for children diagnosed with autism, ADHD or other developmental problems from toxic heavy metals found in many popular products sold in recent years.